BIONIK Laboratories to Participate at MEDICA, a Leading International Trade Show for the Medical Industry

Company to Showcase its InMotion® Robotic Therapy Systems at the World’s Largest Medical Industry Event

TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its participation in the MEDICA Trade Show in Dusseldorf, Germany from November 15–18, 2021. MEDICA, the world forum for the medical industry, brings together leaders in medical technologies and equipment. BIONIK will have a booth located at 4H46 – Hall 4 – Physiotherapy and Orthopedics to showcase its InMotion® Robotic Therapy Systems.

At MEDICA, the Company will highlight InMotion®’s ability to deliver intensive therapy to help patients regain motor function following a stroke and other neurological conditions or injuries. InMotion® therapy guides the patient through specific tasks, aiming to improve motor control of the arm and hand by increasing strength, range of motion and coordination, and assisting with the provision of efficient, effective and intensive sensorimotor therapy. While attending the conference, BIONIK will focus on expanding and strengthening global distribution partners for InMotion®, specifically within Europe.

“MEDICA is the world’s largest medical industry event, attended by thousands of potential buyers of innovative medical technologies. Our presence at MEDICA gives us the opportunity to showcase our industry-leading solutions in front of a global audience of health professionals who can utilize InMotion® therapy systems within their organizations,” said Richard Russo, Jr., Chief Financial Officer and Interim Chief Executive Officer of BIONIK. “We look forward to the opportunity to network with the global healthcare technology community, and to further showcase how our solutions provide more optimal patient outcomes while also impacting the bottom line of the healthcare facility where it is in use.”

InMotion® Robots were developed according to the principles of motor learning and neuro-plasticity, using AI and measuring 200 times a second the position, the speed and the acceleration of the upper limb. Over the last year, BIONIK has seen a 72 percent increase in patient sessions on its robotic devices. The results center around the Company’s emphasis on technology adoption with its partner facilities to ensure successful utilization and patient results. Through patient data securely collected from the Company’s cloud-based data analytics solution, InMotion Connect™, and its approach to hands-on training with clinical staff, BIONIK’s partners establish a long-term partnership to continue to improve the lives of patients. The InMotion® robotic therapy systems are used regularly in more than 15 countries to help stroke survivors and those with other neurological conditions regain movement by training shoulder protraction/retraction, flexion/extension, abduction/adduction, internal/external rotation and elbow flexion/extension. To learn more, please visit

About BIONIK Laboratories Corp.

BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development.

For more information, please visit and connect with us on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the impact on the Company’s business as a result of the Covid-19 pandemic, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

Media contact:
Ashley Willis
FischTank PR

Investor Relations Contact:
Stephanie Prince
PCG Advisory

Source: BIONIK Laboratories Corp.